VolitionRx Limited

NYSEAM:VNRX Stock Report

Market Cap: US$58.4m

VolitionRx Management

Management criteria checks 3/4

VolitionRx's CEO is Cameron Reynolds, appointed in Jan 2010, has a tenure of 13.25 years. total yearly compensation is $772.93K, comprised of 50.6% salary and 49.4% bonuses, including company stock and options. directly owns 1.59% of the company’s shares, worth $929.43K. The average tenure of the management team and the board of directors is 3.9 years and 3.4 years respectively.

Key information

Cameron Reynolds

Chief executive officer

US$772.9k

Total compensation

CEO salary percentage50.6%
CEO tenure15yrs
CEO ownership1.6%
Management average tenure3.9yrs
Board average tenure3.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Cameron Reynolds's remuneration changed compared to VolitionRx's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$30m

Jun 30 2024n/an/a

-US$32m

Mar 31 2024n/an/a

-US$35m

Dec 31 2023US$773kUS$391k

-US$35m

Sep 30 2023n/an/a

-US$34m

Jun 30 2023n/an/a

-US$33m

Mar 31 2023n/an/a

-US$31m

Dec 31 2022US$761kn/a

-US$30m

Sep 30 2022n/an/a

-US$31m

Jun 30 2022n/an/a

-US$30m

Mar 31 2022n/an/a

-US$28m

Dec 31 2021US$982kn/a

-US$27m

Sep 30 2021n/an/a

-US$24m

Jun 30 2021n/an/a

-US$21m

Mar 31 2021n/an/a

-US$21m

Dec 31 2020US$563kUS$364k

-US$20m

Sep 30 2020n/an/a

-US$19m

Jun 30 2020n/an/a

-US$19m

Mar 31 2020n/an/a

-US$18m

Dec 31 2019US$518kUS$391k

-US$16m

Sep 30 2019n/an/a

-US$17m

Jun 30 2019n/an/a

-US$17m

Mar 31 2019n/an/a

-US$18m

Dec 31 2018US$660kUS$398k

-US$18m

Compensation vs Market: Cameron's total compensation ($USD772.93K) is about average for companies of similar size in the US market ($USD645.47K).

Compensation vs Earnings: Cameron's compensation has increased whilst the company is unprofitable.

CEO

Cameron Reynolds (53 yo)

15yrs

Tenure

US$772,933

Compensation

Mr. Cameron Reynolds, MBA, founded VolitionRX in 2010 and has been its President, Chief Executive Officer and Director since October 6, 2011. Mr. Reynolds has been Independent Non-Executive Director of Pat...

Leadership Team

NamePositionTenureCompensationOwnership
Cameron Reynolds
Founder15yrsUS$772.93k1.59%
$ 929.4k
Gaetan Michel
Chief Operating Officer3.9yrsUS$667.81k0.052%
$ 30.4k
Salvatore Butera
Chief Executive Officer of Volition Veterinary Diagnostics Development LLC3.7yrsUS$619.79k0.27%
$ 157.2k
Terig Hughes
CFO & Treasurer3.9yrsUS$513.23k0.092%
$ 53.5k
Jacob Micallef
Chief Scientific Officer10yrsUS$657.89k0.35%
$ 203.5k
Nicholas Plummer
Group General Counsel3.2yrsno data0.086%
$ 50.0k
Louise Batchelor Day
Group Chief Marketing & Communications Officer8.8yrsno data0.074%
$ 43.3k
Gael Forterre
Chief Commercial Officer3.9yrsno data0.14%
$ 79.9k
Sharon Ballesteros
U.S. Head of Quality & Development Process2.8yrsno datano data
Andrew Retter
Chief Medical Officerless than a yearno datano data
Rodney Rootsaert
Corporate Secretary13.3yrsUS$262.72k0.074%
$ 43.3k
Jasmine Kway
Chief Executive Officer of Singapore Volition6.6yrsno data0.092%
$ 53.9k

3.9yrs

Average Tenure

53yo

Average Age

Experienced Management: VNRX's management team is considered experienced (3.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Cameron Reynolds
Founder13.3yrsUS$772.93k1.59%
$ 929.4k
Timothy Still
Chairmanless than a yearno data0.094%
$ 55.1k
Guy Innes
Lead Independent Director13.3yrsUS$61.94k2.77%
$ 1.6m
Mickie Henshall
Independent Director2.4yrsUS$2.22k0.020%
$ 11.8k
Ethel Rubin
Independent Directorless than a yearno datano data
Mark Eccleston
Member of Scientific Advisory Boardless than a yearUS$252.77kno data
Phillip Barnes
Independent Non-Executive Director5.3yrsUS$61.94k0.016%
$ 9.3k
Alan Colman
Member of Scientific Advisory Board & Independent Non Executive Director13.3yrsUS$86.00k0.19%
$ 112.0k
Axel Imhof
Member of Scientific Advisory Board6yrsno datano data
Kim Nguyen
Independent Director3.8yrsUS$61.94k0.073%
$ 42.4k
Timothy Fan
Member of Scientific Advisory Board3yrsno datano data
Alexander Hoffmann
Member of Scientific Advisory Board2yrsno datano data

3.4yrs

Average Tenure

55.5yo

Average Age

Experienced Board: VNRX's board of directors are considered experienced (3.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 23:44
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

VolitionRx Limited is covered by 12 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raymond MyersBenchmark Company
Jan WaldBenchmark Company
Bruce JacksonBenchmark Company